iconstar paper   Aging & Perinatally HIV Infected Articles  
Back grey arrow rt.gif
 
 
Lower Newborn Bone Mineral Content Associated
With Maternal Use of Tenofovir Disoproxil Fumarate
 
 
  CROI 2014
 
Abstract Body
 
Background:
The impact of maternal tenofovir disoproxil fumarate (TDF) use on infant bone mass has not been well studied. Methodology: Two groups of HIV-exposed, uninfected newborns >36 weeks gestational age [GA] were enrolled in this substudy of the US multisite Pediatric HIV AIDS Cohort Study. The TDF group included infants whose mothers used ≥8 weeks of TDF in the 3rd trimester; the nonTDF group included infants whose mothers used no TDF during the pregnancy. Within 4 weeks of birth, a whole body (WB) dual-energy X-ray absorptiometry (DXA) scan was obtained to measure WB bone mineral content (BMC) with head (WBWH) and less head (WBLH). Standardized analysis of scans was performed centrally. Maternal demographic/clinical data were prospectively collected. Infant weight/length were measured within 72 hours of birth. Target sample size was 75 (63 evaluable) per group to detect WBWH BMC difference between groups of 7% or 0.5 standard deviation (SD) with 80% power. Differences in covariates by TDF group were evaluated by Chi-square and Wilcoxon test. Linear regression models were fit to evaluate BMC by TDF group, adjusted and unadjusted for potential confounders.
 
Results: 74 TDF and 69 nonTDF group infants from 14 sites had evaluable DXA scans. Maternal TDF use varied by site (p<.001). Compared to the nonTDF group, TDF group mothers were more likely to be married (31% vs 22%, p=.035) and use boosted protease inhibitors (bPI) (86% vs 64%, p=.005); the groups were similar on demographics, infant weight (p=.159) and length (p= .21) z-scores and GA (p=.60). Among mothers with values available in 3rd trimester for CD4 (63 in TDF;44 in nonTDF) and viral load [VL] (62 in TDF; 50 in nonTDF), similar proportions of TDF and nonTDF group mothers had CD4 ≥ 250 (94% and 93%, respectively) and VL < 400 copies/mL (90% and 90%, respectively). The unadjusted mean infant WBWH BMC was significantly lower in the TDF group (56g vs 64g, p=.002, 12.2%, 0.5 SD) as was the mean WBLH BMC (33 g vs 36g, p=.038, 8.3%, 0.3 SD). These differences persisted after adjusting individually for site; maternal bPI use, age, smoking, and pre-pregnancy body mass index; and infant GA, race/ethnicity, age at DXA and length. Maternal CD4 and VL during the 3rd trimester were not correlated with WBWH BMC (p=.44 and p=.13, respectively) or WBLH BMC (p=.29 and p=.34, respectively). Adjusted for site, maternal bPI use, age, and smoking, and infant body length, race/ethnicity and age at DXA, the mean WBWH BMC and mean WBLH BMC were lower in the TDF group than in the nonTDF group by 6.3g (p = .004) and 2.6 g (p = .056), respectively.
 
Conclusions: Maternal TDF use is associated with a significant reduction in neonatal BMC that persists after adjustment for other factors. The duration and clinical significance of this finding merit evaluation in longitudinal studies.

1205221

1205222

1205223

1205224

1205225

1205226

1205227

1205228

1205229

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org